| scholarly article | Q13442814 |
| P2093 | author name string | Christian Burri | |
| Caecilia Schmid | |||
| Johannes Blum | |||
| P433 | issue | 1 | |
| P921 | main subject | African trypanosomiasis | Q203133 |
| trypanosomiasis | Q2443552 | ||
| P304 | page(s) | 55-64 | |
| P577 | publication date | 2005-09-12 | |
| P1433 | published in | Acta Tropica | Q15762560 |
| P1476 | title | Clinical aspects of 2541 patients with second stage human African trypanosomiasis | |
| P478 | volume | 97 |
| Q35126629 | A mixed methods study of a health worker training intervention to increase syndromic referral for gambiense human African trypanosomiasis in South Sudan. |
| Q34163935 | Actigraphy in human African trypanosomiasis as a tool for objective clinical evaluation and monitoring: a pilot study |
| Q39061942 | African sleeping sickness |
| Q46057445 | African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase |
| Q28474798 | Cardiac alterations in human African trypanosomiasis (T.b. gambiense) with respect to the disease stage and antiparasitic treatment |
| Q37298867 | Cardiac involvement in African and American trypanosomiasis |
| Q33825602 | Cardiac involvement with parasitic infections |
| Q92446512 | Clinical Study on the Melarsoprol-Related Encephalopathic Syndrome: Risk Factors and HLA Association |
| Q61809084 | Clinical and Neuropathogenetic Aspects of Human African Trypanosomiasis |
| Q34319076 | Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness). |
| Q28477304 | Clinical presentation of T.b. rhodesiense sleeping sickness in second stage patients from Tanzania and Uganda |
| Q35126176 | Clinical profiles, disease outcome and co-morbidities among T. b. rhodesiense sleeping sickness patients in Uganda |
| Q37932024 | Contribution of innate immune responses towards resistance to African trypanosome infections |
| Q34395455 | Diagnostic work-up of neurological syndromes in a rural African setting: knowledge, attitudes and practices of health care providers |
| Q38283759 | Escape mechanisms of African trypanosomes: why trypanosomosis is keeping us awake |
| Q28476451 | Focus-specific clinical profiles in human African Trypanosomiasis caused by Trypanosoma brucei rhodesiense |
| Q35345427 | From health advice to taboo: community perspectives on the treatment of sleeping sickness in the Democratic Republic of Congo, a qualitative study |
| Q92661713 | Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment |
| Q36709954 | Haematological and immunological characteristics of eastern hellbenders (Cryptobranchus alleganiensis alleganiensis) infected and co-infected with endo- and ectoparasites |
| Q40519311 | Human African Trypanosomiasis Encephalitis in the United States: Serial Magnetic Resonance Imaging |
| Q56135184 | Human African trypanosomiasis |
| Q58842320 | Human African trypanosomiasis |
| Q43461502 | Human African trypanosomiasis in Angola: clinical observations, treatment, and use of PCR for stage determination of early stage of the disease |
| Q34293008 | Human African trypanosomiasis in South Sudan: how can we prevent a new epidemic? |
| Q37929054 | Human African trypanosomiasis in endemic populations and travellers |
| Q36740553 | Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. |
| Q40595918 | Human Leukocyte Antigen-G: A Promising Prognostic Marker of Disease Progression to Improve the Control of Human African Trypanosomiasis |
| Q27010326 | Imaging African trypanosomes |
| Q34058294 | In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sickness |
| Q34500886 | In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness |
| Q64296317 | Integration of Human African Trypanosomiasis Control Activities into Primary Health Services in the Democratic Republic of the Congo: A Qualitative Study of Stakeholder Perceptions |
| Q40633362 | Maintenance of B cells during chronic murine Trypanosoma brucei gambiense infection |
| Q26786020 | Malaria endemicity and co-infection with tissue-dwelling parasites in Sub-Saharan Africa: a review |
| Q47548444 | Microbial Pre-exposure and Vectorial Competence of Anopheles Mosquitoes |
| Q55322154 | Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo. |
| Q51740583 | Neural Damage in Experimental Trypanosoma brucei gambiense Infection: Hypothalamic Peptidergic Sleep and Wake-Regulatory Neurons. |
| Q92264389 | New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice |
| Q53906272 | New insights in staging and chemotherapy of African trypanosomiasis and possible contribution of medicinal plants. |
| Q39223286 | Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo |
| Q38124745 | Pain management in neurocritical care. |
| Q91913066 | Passive Screening and Diagnosis of Sleeping Sickness with New Tools in Primary Health Services: An Operational Research |
| Q90050028 | Possible influence of Plasmodium/Trypanosoma co-infections on the vectorial capacity of Anopheles mosquitoes |
| Q92966978 | Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo |
| Q35207890 | Prevalence and types of coinfections in sleeping sickness patients in kenya (2000/2009). |
| Q36198356 | Prevalence and under-detection of gambiense human African trypanosomiasis during mass screening sessions in Uganda and Sudan |
| Q38102421 | Rapid diagnostic tests for neurological infections in central Africa |
| Q27011766 | Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis |
| Q44588565 | Sleep and rhythm changes at the time of Trypanosoma brucei invasion of the brain parenchyma in the rat. |
| Q34070616 | Sleeping sickness in travelers - do they really sleep? |
| Q47648890 | Sleeping sickness is a circadian disorder |
| Q34563648 | Syndromic algorithms for detection of gambiense human African trypanosomiasis in South Sudan |
| Q93075160 | The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis |
| Q91964738 | The Flipside of Eradicating a Disease; Human African Trypanosomiasis in a Woman in Rural Democratic Republic of Congo: A Case Report |
| Q33395338 | The burden of human African trypanosomiasis |
| Q64360271 | The detection and treatment of human African trypanosomiasis |
| Q33395342 | The natural progression of Gambiense sleeping sickness: what is the evidence? |
| Q36499156 | The use of Loop-mediated Isothermal Amplification (LAMP) to detect the re-emerging Human African Trypanosomiasis (HAT) in the Luangwa and Zambezi valleys |
| Q37879203 | Therapy of vector-borne protozoan infections in nonendemic settings |
| Q33660251 | Tip-DC development during parasitic infection is regulated by IL-10 and requires CCL2/CCR2, IFN-gamma and MyD88 signaling |
| Q36551049 | Treatment options for second-stage gambiense human African trypanosomiasis |
| Q28555225 | Trypanosoma brucei Invasion and T-Cell Infiltration of the Brain Parenchyma in Experimental Sleeping Sickness: Timing and Correlation with Functional Changes |
| Q37744965 | Trypanosomiasis, cardiomyopathy and the risk of ischemic stroke |
| Q41152853 | Vertical transmission of human African trypanosomiasis: Clinical evolution and brain MRI of a mother and her son. |
Search more.